In 2020, we designed the core vision for Complete360: a scalable platform capable of measuring thousands of proteins from plasma, laying the foundation for the clinical measurement layer of the human proteome.
The Conceptual Birth of the Complete360® Platform
By 2020, years of experience in targeted proteomics had revealed a powerful and somewhat unexpected insight: many proteins that initially appeared undetectable could in fact become measurable once detection parameters were extensively optimized.
Through repeated experiments targeting difficult peptides, Qing Wang and his team observed dramatic differences in detection performance before and after systematic optimization of mass spectrometry conditions. Adjustments in sample preparation workflows, peptide enrichment strategies, instrument acquisition parameters, and quantitative assay design often transformed previously undetectable signals into reproducible measurements.
This observation led to a critical realization.
The main limitation in proteomics was not necessarily the absence of proteins in clinical samples—but rather the lack of sufficiently optimized detection systems capable of measuring them.
From Individual Assay Optimization to Proteome-Scale Thinking
In targeted proteomics, researchers often design assays for a limited number of proteins. For particularly challenging targets, extensive optimization may be required to achieve reliable detection. Through this process, Wang’s team repeatedly saw that systematic method optimization could unlock signals that were previously invisible.
These experiences gradually led to a broader hypothesis:
If enough effort is invested in optimizing detection methods across thousands of targets, it may eventually become possible to measure a far larger portion of the human proteome than previously thought possible—potentially even from complex clinical samples such as plasma.
This idea represented a shift from developing individual assays to designing a platform capable of scaling assay optimization across the entire proteome.
The Birth of the Complete360® Concept
The Complete360® concept emerged from this insight. Rather than treating proteomics as a collection of isolated experiments, Wang envisioned a comprehensive platform that would systematically optimize detection conditions across thousands of proteins.
Achieving this goal would require integrating advances across multiple layers of the workflow, including:
- high-efficiency protein enrichment strategies
- optimized peptide detection parameters
- improved mass spectrometry acquisition methods
- scalable quantitative peptide libraries
- computational pipelines for large-scale proteomics analysis
Together, these components would enable the systematic expansion of proteome coverage from complex biological samples.
Toward Measuring the Entire Human Plasma Proteome
One of the most ambitious goals behind the Complete360® concept was the ability to systematically measure proteins directly from plasma and other body fluids—some of the most information-rich yet technically challenging biological matrices in human biology.
Plasma proteins span an extraordinary dynamic range, where a handful of highly abundant proteins can mask thousands of low-abundance molecules. For decades, this complexity has limited the depth and reproducibility of proteomic measurements in blood.
However, Wang’s work suggested a different conclusion: many proteins previously considered “undetectable” were not absent, but simply beyond the reach of existing detection methods. Through systematic optimization of enrichment strategies, detection parameters, and mass spectrometry workflows, progressively deeper layers of the plasma proteome could be revealed.
These observations led to a bold hypothesis that ultimately shaped the Complete360® platform vision—that with sufficient methodological engineering, it may become possible to systematically measure a large fraction of the human plasma proteome, and ultimately enable detection of virtually all human proteins, unlocking a new molecular layer for early disease detection and precision medicine.
From Concept to Platform
These insights formed the intellectual foundation for what would later become the Complete360® platform, designed to enable ultra-deep measurement of proteins across clinical samples.
Rather than focusing on a limited set of biomarkers, the platform was envisioned as a systematic measurement infrastructure capable of expanding the detectable portion of the human proteome through large-scale method optimization and engineering.
What began as a methodological observation—seeing dramatic improvements in detection through careful optimization—ultimately evolved into a much larger ambition: to make the human proteome measurable at scale and unlock a new molecular layer of precision medicine.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.